Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- LYRA
- Price
- 1.35
- Stock movement down
- -0.04 (-2.88%)
- Company name
- Lyra Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.40M
- Ent value
- 28.38M
- Price/Sales
- 3.99
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -59.40%
- 1 year return (CAGR)
- -87.14%
- 3 year return (CAGR)
- -78.35%
- 5 year return (CAGR)
- -69.72%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
LYRA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.99 |
| Price to Book | - |
| EV to Sales | 47.30 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.77M |
| EPS (TTM) | -18.64 |
| FCF per share (TTM) | -19.36 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 600.00K |
| Gross profit (TTM) | 300.00K |
| Operating income (TTM) | -34.94M |
| Net income (TTM) | -32.95M |
| EPS (TTM) | -18.64 |
| EPS (1y forward) | -7.02 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 50.00% |
| Operating margin (TTM) | -5822.50% |
| Profit margin (TTM) | -5491.17% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 22.05M |
| Net receivables | 0.00 |
| Total current assets | 23.02M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 23.14M |
| Total assets | 43.71M |
| Accounts payable | 627.00K |
| Short/Current long term debt | 31.38M |
| Total current liabilities | 9.48M |
| Total liabilities | 48.04M |
| Shareholder's equity | -4.33M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -34.15M |
| Capital expenditures (TTM) | 78.00K |
| Free cash flow (TTM) | -34.22M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -75.38% |
| Return on Invested Capital | -9254.78% |
| Cash Return on Invested Capital | -9613.20% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.42 |
| Daily high | 1.45 |
| Daily low | 1.28 |
| Daily Volume | 24K |
| All-time high | 889.00 |
| 1y analyst estimate | 16.00 |
| Beta | -0.06 |
| EPS (TTM) | -18.64 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| LYRA | S&P500 | |
| Current price drop from All-time high | -99.85% | -1.82% |
| Highest price drop | -99.85% | -56.47% |
| Date of highest drop | 12 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -73.28% | -10.84% |
| Avg time to new high | 728 days | 12 days |
| Max time to new high | 1455 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.40M
Marketcap category
Small-cap
Description
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Employees
30
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page